Vivos Therapeutics, Inc. Earnings Per Share Disclosure

NOTE 13 - NET LOSS PER SHARE OF COMMON STOCK

 

Basic and diluted net loss per share of Common Stock (“EPS”) is computed by dividing (i) net loss (the “Numerator”), by (ii) the weighted average number of shares of Common Stock outstanding during the period (the “Denominator”).

 

The calculation of diluted EPS is also required to include the dilutive effect, if any, of stock options, unvested restricted stock awards, convertible debt and Preferred Stock, and other Common Stock equivalents computed using the treasury stock method, in order to compute the weighted average number of shares outstanding. As of December 31, 2024 and 2023, all Common Stock equivalents were antidilutive.

 

Presented below are the calculations of the Numerators and the Denominators for basic and diluted EPS (dollars in thousands, except per share amounts):

 SCHEDULE OF COMPUTATION OF ANTI-DILUTIVE WEIGHTED-AVERAGE SHARES OUTSTANDING

		2024				2023
Calculation of Numerator:
Net loss		$	(11,136	)			(13,583	)
Loss applicable to common stockholders		$	(11,136	)		$	(13,583	)
Calculation of Denominator:
Weighted average number of shares of Common Stock outstanding			5,019,886				1,219,381
Net loss per share of Common Stock (basic and diluted)		$	(2.22	)		$	(11.14	)

 

As of December 31, 2024 and 2023, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share of Common Stock since the impact of inclusion was antidilutive (in thousands):

 SCHEDULE OF OUTSTANDING COMMON STOCK SECURITIES NOT INCLUDED IN THE COMPUTATION OF DILUTED NET LOSS PER SHARE

		2024				2023
Common stock warrants			9,658				2,821
Common stock options			1,238				127
Total			10,896				2,948